Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al.
Grossman
E
E
Internal Medicine D, The Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel. gross-e@zahav.net.il
D000419:Albuminuria / Q000517:prevention & control*; D001795:Blood Pressure Determination; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000517:prevention & control*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000175:diagnosis*; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007676:Kidney Failure, Chronic / Q000517:prevention & control; D008297:Male; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors; D000077154:Rosiglitazone; D012680:Sensitivity and Specificity; D013844:Thiazoles / Q000008:administration & dosage*; D045162:Thiazolidinediones
D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone